12:00 AM
 | 
Sep 22, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Belinostat: Phase II data

In a Phase II trial in 35 patients with ovarian cancer, belinostat plus carboplatin and paclitaxel produced 3 complete responses and 12 partial responses. Median duration of response was 5.3 months, and 6...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >